Shares of Marksans Pharma Limited surged nearly 4% after the company announced that its manufacturing facility at Plot A-1, Phase 1-A, Verna Industrial Estate, Verna, Goa, has received approval from the Australian Therapeutic Goods Administration (TGA) for manufacturing pharmaceutical formulations intended for the Australian market.
The approval allows Marksans Pharma to manufacture solid dosage forms, including tablets and hard capsules, at its Goa facility. These products will be marketed and distributed in Australia through its subsidiary, Nova Pharmaceuticals Australasia Pty Ltd. This regulatory clearance strengthens Marksans Pharma’s global manufacturing and distribution network, reaffirming its compliance with international quality standards.
Marksans Pharma, headquartered in Mumbai, India, specializes in research, manufacturing, and marketing of generic pharmaceutical formulations across various therapeutic segments, including cardiovascular, central nervous system, anti-diabetic, pain management, gastroenterological, and anti-allergy medications. The company’s manufacturing facilities in India, the USA, and the UK have received approvals from multiple global regulatory agencies, including the US FDA, UK MHRA, and Australian TGA.
This latest development enhances the company’s global footprint and is expected to contribute positively to its revenue from international markets.
